Lilly (Eli)LLYEarnings & Financial Report
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.
LLY Q4 FY2025 Key Financial Metrics
Revenue
$19.3B
Gross Profit
$15.9B
Operating Profit
$8.3B
Net Profit
$6.6B
Gross Margin
82.5%
Operating Margin
42.8%
Net Margin
34.4%
YoY Growth
42.6%
EPS
$7.39
Lilly (Eli) Q4 FY2025 Financial Summary
Lilly (Eli) reported revenue of $19.3B (up 42.6% YoY) for Q4 FY2025, with a net profit of $6.6B (up 50.5% YoY) (34.4% margin). Cost of goods sold was $3.4B, operating expenses totaled $7.7B.
Key Financial Metrics
| Total Revenue | $19.3B |
|---|---|
| Net Profit | $6.6B |
| Gross Margin | 82.5% |
| Operating Margin | 42.8% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
Lilly (Eli) Q4 FY2025 revenue of $19.3B breaks down across 13 segments, led by Other at $5.4B (28.1% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Other | $5.4B | 28.1% |
| Zepbound | $4.2B | 21.9% |
| Mounjaro | $4.1B | 21.5% |
| Verzenio | $997.1M | 5.2% |
| Collaborationand Other Revenue | $991.7M | 5.1% |
| Taltz | $724.3M | 3.8% |
| Trulicity | $692.8M | 3.6% |
| Other Cardiometabolic Health | $524.5M | 2.7% |
| Other Oncology | $514.8M | 2.7% |
| Jardiance | $465.8M | 2.4% |
| Neuroscience | $320.2M | 1.7% |
| Other Immunology | $187.3M | 1.0% |
| Other Product Total | $77.0M | 0.4% |
Lilly (Eli) Revenue by Segment — Quarterly Trend
Lilly (Eli) revenue by segment across the last 4 reported quarters, showing how each business line (such as Other and Zepbound) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Other | $5.4B | $5.0B | $3.9B | $3.1B |
| Zepbound | $4.2B | $3.6B | $3.4B | $2.3B |
| Mounjaro | $4.1B | $3.6B | $3.3B | $2.7B |
| Verzenio | $997.1M | $880.3M | $929.0M | $657.6M |
| Collaborationand Other Revenue | $991.7M | $1.3B | $831.7M | $1.1B |
Lilly (Eli) Annual Revenue by Year
Lilly (Eli) annual revenue history includes year-by-year totals (for example, 2025 revenue was $65.2B).
Lilly (Eli) Quarterly Revenue & Net Profit History
Lilly (Eli) results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $19.3B | +42.6% | $6.6B | 34.4% |
| Q3 FY2025 | $17.6B | +53.9% | $5.6B | 31.7% |
| Q2 FY2025 | $15.6B | +37.6% | $5.7B | 36.4% |
| Q1 FY2025 | $12.7B | +45.2% | $2.8B | 21.7% |
| Q4 FY2024 | $13.5B | +44.7% | $4.4B | 32.6% |
| Q3 FY2024 | $11.4B | +20.4% | $970.3M | 8.5% |
| Q2 FY2024 | $11.3B | +36.0% | $3.0B | 26.3% |
| Q1 FY2024 | $8.8B | +26.0% | $2.2B | 25.6% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.77B | $11.30B | $11.44B | $13.53B | $12.73B | $15.56B | $17.60B | $19.29B |
| YoY Growth | 26.0% | 36.0% | 20.4% | 44.7% | 45.2% | 37.6% | 53.9% | 42.6% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $63.94B | $71.87B | $75.61B | $78.71B | $89.39B | $100.92B | $114.94B | $112.48B |
| Liabilities | $51.13B | $58.31B | $61.37B | $64.52B | $73.62B | $82.65B | $91.14B | $85.94B |
| Equity | $12.81B | $13.56B | $14.24B | $14.19B | $15.76B | $18.27B | $23.79B | $26.54B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $1.17B | $1.47B | $3.71B | $2.47B | $1.67B | $3.09B | $8.84B | $3.22B |